Biocon in a filing to the stock exchanges informed that the European Directorate for the Quality of Medicines & HealthCare (EDQM) conducted a GMP inspection of an API manufacturing site of Biocon in Bangalore.

As per the filing, the inspection was held between September 12-14, 2022 and issued a list of deficiencies on October 5, 2022. There were no critical deficiencies and one deficiency was cited under the category 'Major'.

"The company will be responding to the agency with appropriate corrective and preventive actions within the stipulated time. Biocon remains committed to the Quality, Safety & Efficacy of its products," the company said in a regulatory filing.